United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 5 ml - for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. none known.

United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - carnitor ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. carnitor ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg

United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg - carnitor® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. carnitor® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - sunitinib - capsule, hard - 12.5 milligram(s) - protein kinase inhibitors; sunitinib

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - sunitinib - capsule, hard - 25 milligram(s) - protein kinase inhibitors; sunitinib

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - sunitinib - capsule, hard - 50 milligram(s) - protein kinase inhibitors; sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib